SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

SPY002

SYRE·Spyre Therapeutics, Inc.
BULLISH
Drug Impact Rating6/10
Trial phase
Phase 2
Time to market
SPY002 is in Phase 2 development. If SKYLINE Part B (combination) data in Q3 2027 is positive, a Phase 3 program would follow. Assuming successful development, potential approval would be several years away, likely in the 2029-2031 timeframe.
Why 6/10
The next hard catalyst for SPY002 is the SKYLINE Part B combination-therapy topline data expected in Q3 2027 (~10 months away). SPY002 is one of three major IBD assets at Spyre (alongside SPY001 and SPY003), so while it is a major value driver, the company is not a single-asset binary. The impact score reflects a dated pivotal readout within 6-12 months on a major but not sole pipeline asset.
Actionable Insight BULLISH

The next hard catalyst for SPY002 is the SKYLINE Part B combination-therapy topline data expected in Q3 2027. Positive data would validate Spyre's combination strategy and could drive significant upside; negative data would undermine the entire platform thesis. The company also has SPY072 SKYWAY data and SKYLIGHT HS data as additional catalysts in late 2027/early 2028.

Price Chart

Loading chart...

Executive Summary

SPY002 is Spyre Therapeutics' extended half-life anti-TL1A antibody for inflammatory bowel disease, currently in Phase 2 development. In June 2026, it posted positive 12-week induction data from the open-label Part A of the SKYLINE trial in ulcerative colitis, meeting its primary endpoint with a 10.7-point reduction in Robart's Histopathology Index (p<0.0001) and showing 33% clinical remission and 42% endoscopic improvement. The drug's ~75-day half-life could enable quarterly or twice-annual maintenance dosing, a potential advantage over first-generation competitors. The next major catalyst is the SKYLINE Part B combination-therapy data expected in Q3 2027. Spyre has a strong cash position ($1.1B, runway into H2 2029) and broad analyst support (Strong Buy consensus, mean target $122.53). However, the TL1A space is intensely competitive (Roche, Teva/Sanofi, Merck all have programs), and a sibling molecule (SPY072) recently disappointed in rheumatoid arthritis.

How It Works

SPY002 is a lab-engineered antibody that blocks TL1A, a protein that drives inflammation and scarring in the gut. By neutralizing TL1A, the drug aims to reduce the immune overactivity that causes inflammatory bowel disease (ulcerative colitis and Crohn's disease). Its key innovation is an extended half-life (the drug stays in the body longer), which could allow patients to receive injections every 3 to 6 months instead of every few weeks.

Trial Status

SPY002 completed Part A of the Phase 2 SKYLINE trial (open-label, 12-week induction) with positive topline results announced June 15, 2026. Part B of SKYLINE, evaluating pairwise combinations of SPY001, SPY002, and SPY003, is enrolling ahead of schedule with topline induction data expected in Q3 2027. SPY002 has also completed Phase 1 testing in healthy volunteers, demonstrating a ~75-day half-life and supporting quarterly or twice-annual maintenance dosing.

The Two-Sided Case

▲ Bull Case5
SPY002 met its Phase 2 SKYLINE Part A primary endpoint with a 10.7-point RHI reduction (p<0.0001), plus 33% clinical remission and 42% endoscopic improvement at Week 12, which the company characterizes as among the highest reported in UC.
Extended half-life (~75 days) enables potential quarterly or twice-annual subcutaneous maintenance dosing, a significant convenience advantage over first-generation competitors that require more frequent dosing.
All three IBD monotherapies (SPY001, SPY002, SPY003) achieved positive proof-of-concept in SKYLINE Part A, validating the platform and enabling the combination strategy in Part B.
Strong institutional support: FMR LLC held $1.16B, BlackRock $578M, and multiple funds added/doubled positions in Q2 2026. Analyst consensus is Strong Buy (21 buy-equivalent ratings, 2 hold), with a mean price target of $122.53 (23.4% implied upside).
Cash runway of $1.1B extends into H2 2029, providing ample funding through multiple clinical readouts without near-term dilution risk.
▼ Bear Case5
Intense TL1A competition: Roche (RVT-3101), Teva/Sanofi (duvakitug, Phase 3), and Merck (tulisokibart, Phase 3) are all ahead or at similar stages with first-generation anti-TL1A antibodies, and duvakitug already has positive Phase 2b maintenance data.
SPY072, a sibling anti-TL1A molecule, disappointed in rheumatoid arthritis (SKYWAY trial, August 2026), missing internal benchmarks and causing a stock decline, raising questions about the TL1A platform's breadth.
SKYLINE Part B combination data is not expected until Q3 2027, leaving a long data-free period during which the stock is exposed to competitive readouts and market sentiment.
The company raised $350M in a public offering at $85/share in October 2026, causing dilution, and reported a Q3 2026 net loss of $96.1M.
All three pipeline assets (SPY001, SPY002, SPY003) are still in Phase 2; none have been tested in randomized, blinded trials yet (Part A was open-label).

Upcoming Catalysts

  • SKYLINE Part B combination-therapy topline induction data (Q3 2027)
  • SPY072 SKYWAY trial additional readouts (ongoing)
  • SKYLIGHT trial in hidradenitis suppurativa proof-of-concept data (late 2027/early 2028)
  • Potential partnership or licensing interest given the validated three-asset platform

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report

Sources · 12

Hover a chip for the title
1 ir.spyre.com2 fiercebiotech.com3 fiercebiotech.com4 markets.businessinsider.com5 prnewswire.com6 spyre.com7 tandfonline.com8 biospace.com9 panabee.com10 markets.businessinsider.com11 sec.gov12 sec.gov